{"schema_version":"secwatch.filing_event.v1","accession":"0000805928-24-000070","form_type":"8-K","ticker":"AXGN","cik":"0000805928","company_name":"Axogen, Inc.","filed_at":"2024-05-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:22.021790+00:00","generated_at":"2026-06-03T01:14:29.945559+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Axogen Q1 2024 revenue $41.4M (+12.9% YoY); net loss narrows to $6.6M; adj EBITDA turns positive","bullets":["Revenue $41.4M, up 12.9% YoY; gross margin improved to 78.8% from 77.7%.","Net loss $6.6M ($0.15/sh) vs $7.1M ($0.17/sh) in Q1 2023; adjusted net loss $2.7M ($0.06/sh).","Adjusted EBITDA positive at $1.0M vs loss of $3.8M in prior year.","Cash & investments $23.6M as of March 31, 2024, down from $37.0M at Dec 31, 2023.","Reaffirmed FY2024 revenue guidance $177M-$181M; gross margin 76%-79%; expects positive net cash flow Apr-Dec 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000805928-24-000070","json":"https://secwatch.observer/filing/0000805928-24-000070.json","markdown":"https://secwatch.observer/filing/0000805928-24-000070.md","text":"https://secwatch.observer/filing/0000805928-24-000070.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/805928/000080592824000070/0000805928-24-000070-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/805928/000080592824000070/axgn-20240502.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T01:14:29.945559+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c227c08f388e3d0a01a08decedcfcf2e4469be96","claim":"Axogen, Inc. reported full year 2024 results: revenue 177 million to 181 million. Guidance reaffirmed.","evidence_excerpt":"We are maintaining our annual revenue guidance in the range of $177 million to $181 million, which represents a growth rate of approximately 11% to 14%.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/805928/000080592824000070/0000805928-24-000070-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year 2024"},{"label":"Revenue","value":"177 million to 181 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"f01b61f7b2ffdb173eb4f75d8c31a99c4814c76a","claim":"Axogen, Inc. reported first quarter ended March 31, 2024 results: revenue 41.4 million, net income -6.6 million, EPS -0.15. Guidance reaffirmed.","evidence_excerpt":"First quarter revenue was $41.4 million, a 12.9% increase compared to the first quarter of 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/805928/000080592824000070/0000805928-24-000070-index.htm","confidence":0.98,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Revenue","value":"41.4 million"},{"label":"Net income","value":"-6.6 million"},{"label":"EPS","value":"-0.15"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"f01b61f7b2ffdb173eb4f75d8c31a99c4814c76a","claim":"Axogen, Inc. reported first quarter ended March 31, 2024 results: revenue 41.4 million, net income -6.6 million, EPS -0.15. Guidance reaffirmed.","evidence_excerpt":"nerve injuries, today reported financial results and business highlights fo r the first quarter ended March 31, 2024. First Quarter Financial Results • First quarter revenue was $41.4 million, a 12.9% increase compared to the first quarter of 2023. • In the first quarter of 2024, our gross margin increased to 78.8%, up from 77.7%, as reclassified* in the same quarter","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/805928/000080592824000070/0000805928-24-000070-index.htm","confidence":0.98,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Revenue","value":"41.4 million"},{"label":"Net income","value":"-6.6 million"},{"label":"EPS","value":"-0.15"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}